Former sales rep alleges J&J, Janssen pushed off-label promotion

Related Products

• ePharm5 InDepth

  EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...

• Healthcare Marketing Advisor

  Healthcare Marketing Advisor provides concise, time-saving strategies for branding, promoting, and advertising your...

• Marketing Oncology: Strategies for Service Line Campaigns

  During this 90-minute Webcast, expert healthcare marketers discuss the research and strategic planning that should be the...

• The Complete Guide to Hospital Marketing, Second Edition

  The Complete Guide to Hospital Marketing, Second Edition looks at the complex field of healthcare marketing in a...

• Big Pharma Performance Before, During and Beyond the Global Recession

  This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...

Most Popular

Related Articles

• Eli Lilly to pay $62M for improperly marketing Zyprexa

  Eli Lilly agreed to pay $62 million to 32 states and the District of Columbia to resolve allegations it improperly marketed...

• Pfizer accused of suppressing Neurontin study

  Pfizer marketing executives allegedly knew Neurontin, an epilepsy drug, did not effectively treat other conditions and...

• Lilly to pay $1.4B for alleged off-label promotion

  Eli Lilly’s tab for allegedly promoting its antipsychotic Zyprexa for off-label uses topped $2.6 billion after it...

• Judge rules J&J and Janssen misled physicians

  Johnson & Johnson and its Janssen Pharmaceuticals unit must pay West Virginia roughly $4.5 million for misleading the...

• Biomet under investigation for possible fraud

  Government investigators are examining allegations that Biomet improperly sold, promoted, and billed for its bone growth...